ArticleChinese medical journal2025

Efficacy and safety of chimeric antigen receptor T cell therapy combined with zanubrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Langqi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.